← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Intravacc B.V.
Bilthoven
$13,928,820
Total funding
2
Grants
Funding over time
peak $5M · FY2021–25$10M$7.5M$5M$2.5M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,928,820 · 2
By mechanism
N01$13,928,820 · 2
Investigators at Intravacc B.V.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Advanced Development of a Vaccine for Acute Flaccid Myelitis Associated with Enterovirus D68$5,031,575
N01 · FY2021 · AI
Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases$2,674,055
N01 · FY2024 · AI
DEVELOPMENT OF AN INTRANASAL VACCINE AGAINST GONORRHEA$2,007,498
N01 · FY2022 · AI
Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases$1,174,464
N01 · FY2025 · AI
Advanced Development of a Vaccine for Acute Flaccid Myelitis Associated with Enterovirus D68$1,085,889
N01 · FY2023 · AI
Advanced Development of a Vaccine for Acute Flaccid Myelitis Associated with Enterovirus D68$1,004,130
N01 · FY2025 · AI
DEVELOPMENT OF AN INTRANASAL VACCINE AGAINST GONORRHEA$756,750
N01 · FY2023 · AI
Advanced Development of a Vaccine for Acute Flaccid Myelitis Associated with Enterovirus D68$194,459
N01 · FY2022 · AI